비욘드스프링(BYSI)는 NAS에 상장된 Healthcare · Biotechnology 기업입니다. 현재가 $0.75 (+5.75%), 시가총액 $53.87M.
BeyondSpring Inc., a clinical stage biopharmaceutical company, focuses on developing and selling clinical-stage biopharmaceutical therapies focused on oncology and immunology. The company operates through two segments: the Plinabulin pipeline and the TPD platform. The company's lead asset is Plinabulin, a selective immunomodulating microtubule-binding agent that has completed Phase III clinical trials for treatment of non-small cell lung cancer (NSCLC); and as an anti-cancer agent, as well as for the prevention of chemotherapy-induced neutropenia (CIN). It also develops Plinabulin in combination with Plinabulin+docetaxel vs.
비욘드스프링의 재무제표, 목표주가, 기관투자자(13F) 보유 현황, 관련 뉴스는 XTS에서 실시간으로 확인할 수 있습니다.
비욘드스프링의 현재 주가는 $0.75 (+5.75%)입니다. XTS에서 실시간 시세와 차트를 확인할 수 있습니다.
비욘드스프링의 시가총액은 약 $53.87M입니다.
BeyondSpring Inc., a clinical stage biopharmaceutical company, focuses on developing and selling clinical-stage biopharmaceutical therapies focused on oncology and immunology.